[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Based on the presentation of severe immunosuppression (CD4 90), neurological symptoms, a solitary lesion in the corpus callosum on MRI, and positive Epstein-Barr virus DNA in the CSF, the most likely diagnosis is Primary CNS Lymphoma. This combination of findings is highly characteristic in patients with advanced HIV disease.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is a fusion inhibitor called enfuvirtide (Fuzeon).",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Based on the symptoms (fever, malaise, diarrhea, lymphadenopathy) presenting acutely after exposure, and a positive HIV test with a relatively preserved CD4 count, this patient is most likely currently in the **acute stage** of HIV infection (also known as primary HIV infection or acute retroviral syndrome).",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "Based on the clinical presentation, including the patient's immunocompromised state (low CD4 count), pulmonary symptoms, cavitary lesions on chest X-ray, and the finding of partially acid-fast branching rods on microscopy, the most likely diagnosis is *Nocardia* infection.\n\nThe most appropriate drug for treating *Nocardia* infection, particularly disseminated disease in an immunocompromised patient, is typically trimethoprim-sulfamethoxazole (TMP-SMX).\n\nThe mechanism of action of trimethoprim-sulfamethoxazole involves the sequential inhibition of bacterial folic acid synthesis:\n1.  **Sulfamethoxazole** inhibits the enzyme dihydropteroate synthase, which incorporates para-aminobenzoic acid (PABA) into folic acid precursors.\n2.  **Trimethoprim** inhibits the enzyme dihydrofolate reductase, which converts dihydrofolic acid to tetrahydrofolic acid.\n\nBy blocking these two steps in the pathway, TMP-SMX synergistically inhibits bacterial DNA and RNA synthesis.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "Based on your description, the physician scientist is focusing on the HIV envelope proteins, which are the targets of the natural humoral immune response detected in diagnostic tests. The main envelope proteins are derived from the gp160 precursor and are gp120 and gp41.\n\nOf these, **gp120** is the most likely target. It is the outer glycoprotein subunit responsible for binding to the host cell CD4 receptor and co-receptors. As the outermost protein involved in initial contact and binding, it is a primary target for neutralizing antibodies generated by the immune system and would be a logical target for a therapeutic antibody designed to block viral entry.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "This presentation, especially the biopsy finding of septate hyphae branching at acute angles, is highly suggestive of **Aspergillus** species as the causal organism. The clinical findings of fever, hemoptysis, and a fibrocavitary lesion are consistent with invasive pulmonary aspergillosis in an immunocompromised host like an HIV-positive individual.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Okay, Junior. This is a good clinical scenario highlighting drug interactions, especially in complex patients like those with advanced HIV and opportunistic infections.\n\nThe patient is receiving valganciclovir for CMV colitis and is already on zidovudine, lamivudine, and dolutegravir.\n\nBoth valganciclovir and zidovudine are known to cause bone marrow suppression.\n\nAdding valganciclovir to this regimen, particularly alongside zidovudine, puts the patient at greatest risk for **severe myelosuppression**, specifically **neutropenia** (low white blood cell count) and **anemia** (low red blood cell count). This is due to the additive toxicity of these two medications on the bone marrow.\n\nYou'll need to monitor his complete blood count closely during treatment.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "Thank you for bringing this important question forward. It's understandable that the mother is concerned, and early testing is crucial.\n\nFor diagnosing HIV infection in a newborn baby born to an HIV-positive mother, an **HIV nucleic acid amplification test (NAT)**, such as an **HIV-1 DNA PCR** or **HIV-1 RNA PCR (viral load)**, is the most appropriate test to perform as soon as possible after delivery.\n\nHere's why:\n\n*   Standard HIV antibody tests (like the one used for screening the mother) detect antibodies produced by the body in response to the virus. In a newborn, maternal HIV antibodies can cross the placenta and be present in the baby's blood even if the baby is not infected. A positive antibody test in a newborn thus reflects the mother's status, not necessarily the baby's infection status.\n*   HIV NATs, on the other hand, detect the presence of the virus itself (its genetic material, DNA or RNA). If the virus is detected, it means the baby is infected. This type of test is needed to accurately diagnose HIV infection in infants.\n\nGuidelines recommend performing the initial HIV NAT on the baby typically within the first 14-48 hours of life.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This scenario presents a significant ethical and clinical challenge.\n\n1.  **Maintain Patient Confidentiality:** Your primary duty is to your patient (the husband), and confidentiality is fundamental to the physician-patient relationship. You cannot disclose his diagnosis to his wife without his explicit consent.\n2.  **Counsel the Patient:** You must strongly counsel the patient on the importance of disclosing his diagnosis to his wife due to the risk of transmission. Explain the health implications for her and the options for preventing transmission (e.g., PrEP if she is negative, effective treatment for him). Offer support and resources for disclosure.\n3.  **Involve Public Health:** Explain to the patient that public health departments offer partner notification services. These services can inform partners of potential exposure anonymously, without revealing the source patient's identity. Encourage the patient to utilize this service if he is unwilling to disclose directly.\n\nThe most appropriate next step is to counsel the patient thoroughly about his diagnosis, its implications for his partner, and strongly encourage him to disclose, offering support and suggesting public health partner notification as an alternative if direct disclosure is too difficult for him initially. Disclosing his diagnosis to his wife without his consent is a breach of confidentiality and generally not the appropriate action.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Based on the information provided:\n1.  The patient has acute pancreatitis confirmed by symptoms, elevated enzymes, and CT findings.\n2.  Gallstones are ruled out by the normal gallbladder on CT.\n3.  While alcohol is a common cause, \"moderate social use\" makes it less likely than drug-induced pancreatitis in this context.\n4.  Certain medications, particularly some antiretroviral therapies (ART) used for HIV, are well-known causes of acute pancreatitis.\n5.  Given her recent HIV diagnosis and unknown ART regimen, drug-induced pancreatitis secondary to her HIV medications is a strong possibility and a relatively common cause of pancreatitis in patients on ART.\n\nTherefore, the most likely etiology among the options suggested by her history and findings is drug-induced pancreatitis, specifically related to her antiretroviral therapy.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI). It disrupts the process of **reverse transcription**, which is the synthesis of viral DNA from the viral RNA genome by the enzyme reverse transcriptase. This prevents HIV from replicating within the host cells.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "That's a relevant area of research. Here's a brief overview:\n\n1.  **Latent HIV-1 Infection:**\n    *   DNA methylation is known to play a significant role in establishing and maintaining HIV latency.\n    *   Specifically, methylation patterns at the CpG island in the 5' Long Terminal Repeat (LTR) of the integrated provirus are associated with transcriptional silencing, preventing the virus from replicating.\n    *   There can also be altered methylation patterns in host genes within cells harboring the latent virus, potentially contributing to their characteristics and survival.\n\n2.  **Active HIV-1 Infection:**\n    *   During active, untreated infection, there are more widespread changes in the host cell's epigenome, including DNA methylation.\n    *   These changes occur in various cell types (e.g., T cells, monocytes) and are influenced by chronic inflammation, immune activation, and viral replication itself.\n    *   These host methylation changes can affect gene expression related to immune function, cellular metabolism, inflammation pathways, and contribute to pathogenesis and immune dysfunction seen in active disease.\n\n**In summary:** While methylation contributes to proviral silencing in *latent* infection (key for the reservoir), *active* infection involves broader, systemic changes in host DNA methylation driven by the inflammatory and replicative state. The two profiles reflect distinct phases and impacts of the virus on the host.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]